SCH772984

Catalog No.S7101 Batch:S710108

Print

Technical Data

Formula

C33H33N9O2
Molecular Weight 587.67 CAS No. 942183-80-4
Solubility (25°C)* In vitro DMSO (warmed with 50ºC water bath) 6 mg/mL (10.2 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
10% DMSO 40% PEG 300 5%Tween80 45%ddH2O
0.6mg/ml Taking the 1 mL working solution as an example, add 100 μL of 6 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.
Targets
ERK2 [1]
(Cell-free assay)		 ERK1 [1]
(Cell-free assay)
1 nM 4 nM
In vitro SCH772984 is a novel, selective and ATP competitive inhibitor of ERK1/2. SCH772984 inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner. SCH772984 also inhibits phosphorylation of residues in the activation loop of ERK itself. SCH772984 demonstrates EC50 values <500 nM in approximately 88% and 49% of BRAF-mutant or RAS-mutant tumor lines, respectively. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. [1]
In vivo SCH772984 induces tumor regressions in xenograft models at tolerated doses. SCH772984 effectively inhibites MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models. [1]
Features Does not directly inhibit MEK1, MEK2, BRAF, or CRAF enzyme activity.

Protocol (from reference)

Kinase Assay:

[1]
  • ERK2 IMAP enzymatic assay

    SCH772984 is tested in 8 point dilution curves in duplicate against purified ERK2 or ERK1. The enzyme is added to the reaction plate. and incubated with the compound before adding a solution of substrate peptide and ATP. 14μl of diluted enzyme (0.3ng active ERK2 per reaction) is added to each well of a 384-well plate. The plates are gently shaken to mix the reagents and incubated for 45 minutes at room temperature. The reaction is stopped with 60μl of IMAP Binding Solution (1:2200 dilutions of IMAP beads in 1X Binding Buffer). The plates are incubated at room temperature for an additional 0.5 hours to allow complete binding of phosphopeptides to the IMAP beads. Plates are read on the LJL Analyst.
Cell Assay:

[1]
  • Cell lines

    BRAF-mutant or RAS-mutant tumor lines

  • Concentrations

    ~10 μM

  • Incubation Time

    5 days

  • Method

    Cell proliferation experiments are performed in a 96-well format (six replicates), and cells are plated at 4,000/well density. At 24 h after cell seeding, cells are treated with DMSO or 9 point IC50 dilution (0.001-10 μM) at 1% DMSO final for all concentrations. Viability is assayed on 5 days after dosing using ViaLight luminescence kit following the manufacturer’s recommendations. For cell line panel viability assay, cells are treated with SCH772984 for 4 days and assayed by CellTiterGlo luminescent cell viability assay.
Animal Study:

[1]
  • Animal Models

    Nude mice

  • Dosages

    12.5 mg/kg, 25 mg/kg, 50 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by Leuk Lymphoma, 2014, 1, 8]

, , Biochem Biophys Res Commun, 2017, 485(4):775-781

Data from [Data independently produced by , , Nature, 2016, 534(7609):647-51]

Data from [Data independently produced by , , Cell Research, 2015, 25: 561-573]

Selleck's SCH772984 has been cited by 609 publications

The aging mouse CNS is protected by an autophagy-dependent microglia population promoted by IL-34 [ Nat Commun, 2024, 15(1):383] PubMed: 38195627
PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer [ Cell Rep Med, 2024, 5(2):101420] PubMed: 38382468
The DNA-dependent protein kinase catalytic subunit exacerbates endotoxemia-induced myocardial microvascular injury by disrupting the MOTS-c/JNK pathway and inducing profilin-mediated lamellipodia degradation [ Theranostics, 2024, 14(4):1561-1582] PubMed: 38389837
Tubuloid differentiation to model the human distal nephron and collecting duct in health and disease [ Cell Rep, 2024, 43(1):113614] PubMed: 38159278
A senescence restriction point acting on chromatin integrates oncogenic signals [ Cell Rep, 2024, 43(4):114044] PubMed: 38568812
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers [ Oncologist, 2024, 29(1):15-24] PubMed: 37616543
Cell-free ascites from ovarian cancer patients induces Warburg metabolism and cell proliferation through TGFβ-ERK signaling [ Geroscience, 2024, 10.1007/s11357-023-01056-1] PubMed: 38196068
Hepatitis C virus modified sE2F442NYT as an antigen in candidate vaccine facilitates human immune cell activation [ J Virol, 2024, 98(1):e0180923] PubMed: 38084956
Testosterone reduces hippocampal synaptic damage in an androgen receptor-independent manner [ J Endocrinol, 2024, 260(2)e230114] PubMed: 37991884
p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer [ BMC Cancer, 2024, 24(1):233] PubMed: 38373988

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.